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Abstract
The recent discovery of innate lymphoid cells has revolutionized our understanding of the 
pathogenesis of immune diseases including allergy and asthma. Innate lymphoid cells (ILCs) are a 
heterogeneous collection of lymphocytes that lack antigen-specificity (non-T, non-B cells) and 
potently produce characteristic cytokines of T cell subsets (Th1, Th2, Th17). ILCs are divided into 
group 1 (ILC1s), group 2 (ILC2s), or group 3 (ILC3s). Similar to Th2 cells, ILC2s produce IL-4, 
IL-5, and IL-13, among others, and are present in increased numbers in samples from patients with 
many allergic disorders including asthma and chronic rhinosinusitis (CRS). Animal models have 
identified that ILC2s contribute to eosinophilic tissue infiltration, airway hyperresponsiveness, 
mucus production, as well as coordinate adaptive immune responses. Finally, recent studies 
support regulation of ILC2s by neuro-immune mechanisms as well as demonstrate a significant 
degree of plasticity between ILC subsets that may impact the immune responses in asthma and 
allergic airway diseases. Here, we review the current literature on ILC2s in human asthma and 
allergic airway diseases, as well as highlight some recent mechanistic insights into ILC2 function 
from in vitro studies and in vivo animal models.
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Introduction
Human allergic airway diseases are characterized by eosinophilic inflammation, mucus and 
IgE production, tissue remodeling, and the presence of a distinct cytokine profile that 
includes IL-4, IL-5, IL-9, and IL-13.1 For decades, conventional CD4+ Th2 cells were 
considered the primary orchestrators of the allergic response through production of these 
cytokines. IL-4 mediates Th2 cell differentiation and IgE class switching, IL-5 induces 
eosinophilic tissue infiltration, IL-9 promotes mucus production and mast cell accumulation, 
and IL-13 has pleiotropic functions in airway hyperresponsiveness, remodeling, and 
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inflammation.2 Although conventional CD4+ cells clearly contribute to the type 2 cytokine 
burden present in tissues of patients with allergic inflammation, emerging evidence supports 
a significant, and at times dominant, role for group 2 innate lymphoid cells (ILC2s) in 
promoting allergic type 2 inflammatory responses.3–5
ILC2s are a member of the broader group of innate lymphoid cells (ILCs) that include 
ILC1s, ILC2s, and ILC3s and have cytokine profiles similar to conventional CD4+ Th1, 
Th2, and Th17 cells.6–8 All ILCs develop from common lymphoid progenitors (CLP) and 
depend on inhibitor of DNA binding 2 (Id2), thymocyte selection-associated high-mobility 
group box protein (TOX), nuclear factor interleukin-3 regulated (NFIL3), as well as γ chain 
(γc) and notch signaling.9,10 ILC1s promote immune responses to viruses, intra-cellular 
microbes as well as tumors and produce IFNγ and TNF-α.6,8,11 ILC2s produce Th2 
cytokines and the growth factor amphiregulin and are involved in responses to helminths, 
allergens and some viruses.12,13 ILC3s produce IL-17 and IL-22 and promote neutrophilic 
responses to extracellular bacteria and fungi.6,8,11
The transcription factor expression in ILCs also parallels their T cell counterparts and 
includes T-bet (ILC1s), GATA-3 (ILC2s), and RORgt (ILC3s).7,8,11 ILCs are predominately 
lineage-negative cells (except for NK cells as a member of ILC1s) that do not express 
distinct markers for T cells, B cells, or other known hematopoietic lineage-positive cells. 
Further, ILCs do not express antigen-specific receptors and are directly regulated (activation 
or inhibition) by cytokines, lipid mediators, and some cellecell contact mechanisms.11,12,14 
Interestingly, an additional novel population of IL-10 producing ILCs termed ILCregs were 
recently discovered in IL-10 reporter mice and provide suppressive activities in certain 
conditions.15 Given the lack of specific identifying makers and relatively low numbers of 
ILCs in tissues, ILCs were largely elusive to scientific study until discovery in the past 
decade after sophisticated approaches were applied to detect their presence.
ILC2s are of great interest to the field of allergic diseases as they rapidly produce large 
amounts of Th2 cytokines in tissues after activation.12 Since ILC2s do not require antigen 
recognition, any stimulus (virus, irritant, allergen) that induces cytokines (IL-33, TSLP, 
IL-25) or lipid mediators (PGD2, CysLTs) can activate ILC2 expansion and cytokine 
production.12,14,16 This paradigm can then help to explain exacerbations of type 2 
inflammation that occur after viral or irritant triggers in patients with allergic airway 
diseases including allergic rhinitis, CRS, and asthma. Here, we review the current literature 
regarding ILC2s in human allergic airway disease as well as highlight novel mechanisms of 
ILC2 function.
ILC2s in human allergic airway disease
Animal models have revealed important roles for ILC2s in allergen-and virus-driven lung 
inflammation and AHR suggesting that they may contribute to human allergic airway 
diseases (reviewed in Refs. 12 and 17).12,17 Following the early animal studies, ILC2s were 
subsequently detected at elevated levels in samples from patients with allergic rhinitis, 
chronic rhinosinusitis with nasal polyposis (CRScNP) and asthma.3,16,18,19 A proposed 
model for ILC2 responses in airway remodeling in asthma is depicted in Figure 1.
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Allergic rhinitis
Allergic rhinitis (AR) is considered an IgE-mediated response to inhaled allergens that 
causes rhinorrhea, sneezing, itching, and congestion.20 The pathogenesis of AR involves 
activation and accumulation of many cells including mast cells, T and B cells, basophils, 
eosinophils, and dendritic cells. In the effector phase of AR, allergen binding IgE on mast 
cells leads to cross-linking followed by release of many mediators including histamine, 
CysLTs, and prostaglandins. CysLTs and prostaglandin D2 can specifically activate ILC2s 
and thus link ILC2s with mediators that are rapidly formed during active allergic rhinitis 
symptoms.21–23
Recent human studies have investigated ILC2s in human allergic rhinitis.24–28 We initially 
reported that peripheral blood ILC2s are increased 4 h after nasal cat allergen challenge in 
cat-allergic individuals compared with diluent challenges administered at a separate visit.25 
Another report showed that ILC2s levels were increased in seasonal allergic rhinitis (SAR) 
patients during grass pollen season which was not found in non-atopic subjects.24 
Interestingly, SAR patients treated with SCIT showed reduced ILC2 levels during pollen 
seasons suggesting that immunotherapy modulated circulating ILC2s. A subsequent study 
found increased cytokine-producing ILC2s in peripheral blood of house dust mite (HDM) 
allergic individuals that correlated with symptom severity.27 Interestingly, an additional 
study demonstrated that HDM and mugwort triggered AR had differences in ILC2 responses 
as peripheral blood ILC2s were increased in levels and activation from patients with HDM-
AR compared to mugwort-AR.28 Another group utilized a nasal allergen challenge (NAC) 
model and detected increased nasal mucosal ILC2s 6 h after challenge along with increased 
nasal fluid IL-5, IL-13, as well as chemokines CCL26/ Eotaxin-3, and CCL17/TARC.26 
These reports suggest that ILC2s are recruited early in the allergic nasal response to 
allergens in allergic rhinits.
Early mediators that may be contributing to ILC2 recruitment and activation at this phase of 
reactions include CysLTs and PGD2. However, it could also be that IL-33, an epithelial 
cytokine that activates ILC2s, is also contributing to ILC2 activation in allergic rhinitis. One 
study showed that IgE-activation of human mast cells leads to IL-33 secretion that was 
further processed into more biologically active forms (shorter and more potent forms of 
IL-33)29 and could rapidly and potently activate ILC2s.30 Thymic stromal lymphopoietin 
(TSLP) is another epithelial cytokine that activates ILC2s.31 TSLP has been found increased 
in nasal samples from patients with AR suggesting that it may also have a role in ILC2 
responses in AR.32,33 Notably, there is evidence that IL-33 combined with TSLP can 
synergistically activate human ILC2s.34 Since both mediators may be present in sinonasal 
disease, such combined activity of TSLP and IL-33 has important pathogenic implications.
Although ILC2s are recruited to the nasal mucosa in AR, the precise functions of ILC2s 
once present in the tissue are unclear. Mouse models of AR have significant limitations to 
test in vivo mechanisms present in humans, though one report utilized a ragweed 
sensitization protocol over 3 weeks to evaluate nasal type 2 responses.35 Mice receiving 
ragweed developed nasal mucosal eosinophilia, Th2 cytokine and total IgE increases, as well 
as sneezing. RAG2 knockout mice that have ILC2s but lack T or B cells had significantly 
reduced eosinophilia and sneezing compared with wild type mice suggesting that adaptive 
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immune responses are required to initiate or propagate the eosinophilia. The authors 
suggested that ILC2s are dispensable in this model of AR. However, RAG2 KO mice also 
lack IgE production that may be necessary to initiate ILC2 activation through mast cell 
mediator secretion. Thus, the role of ILC2s in vivo in AR needs further investigation, and in 
addition to AR, ILC2s are also good candidates to promote eosinophilia in non-allergic 
rhinitis with eosinophilia (so-called NARES). NARES is characterized by nasal eosinophilia 
without evidence of systemic allergic sensitization. As ILC2s can directly promote 
eosinophilia through IL-5 secretion without effects on allergen-specific IgE production, this 
suggests that ILCs could contribute to NARES.
Chronic rhinosinusitis
Chronic rhinosinusitis with (CRSwNP) or without (CRSsNP) nasal polyps is a major cause 
of morbidity for patients and is associated with worsened asthma. Several reports have 
shown that ILC2s are enriched in nasal polyps and ILC2 numbers correlate positively with 
polyp and blood eosinophils as well as symptoms.19,36–39 As ILC2s are potent producers of 
IL-5, the finding that ILC2s are enriched in eosinophilic nasal polyps suggests that they may 
be involved in eosinophil recruitment and persistence in nasal polyps. Further, elevated 
levels of PGD2, CysLTs, TSLP, and IL-33 (that all activate ILC2s) have been detected in 
CRS tissue.40,42–44 IL-33-and TSLP-stimulated nasal polyp ILC2s produce Th2 cytokines 
including IL-5 that is dependent on the Th2 transcription factor GATA-3, highly expressed 
by ILC2s.34 Interestingly, a recent report additionally showed that solitary chemosensory 
cells (SCCs) that express taste receptors are a dominant source of IL-25, an epithelial 
cytokine that was one of the first shown to activate ILC2s.45,46 SCCs were found to be 
increased in number along with ILC2s in nasal polyps compared with turbinate tissue.46 
Overall, ILC2s appear to be likely contributors to the pathogenesis of CRS and nasal polyps, 
especially those with eosinophilic disease.
Aspirin Exacerbated Respiratory Disease (AERD)
Aspirin Exacerbated Respiratory Disease (AERD) is characterized by eosinophilic chronic 
rhinosinusitis with nasal polyps, asthma, and respiratory reactions to COX-1 inhibitors such 
as aspirin and NSAIDS.47 Our group recently assessed ILC2 levels from nasal mucosa and 
blood at baseline, during NSAID reactions, and post desensitization in AERD patients.48 
During reactions, ILC2s were recruited to the nasal mucosa and reduced in the blood in 
AERD patients. Urinary LTE4 and PGD2 metabolites were increased during reactions and 
ILC2 levels correlated with symptom severity scores. Previous work has demonstrated that 
AERD tissue samples contain high levels of eosinophils along with increased PGD2, 
CysLTs, IL-33, IL-25 and TSLP.47,49–51 These mediators can all activate ILC2s, either 
additively or synergistically.44,52 Of the chemotactic mediators, PGD2 and CysLTs have 
been shown to induce chemotaxis of ILC2s and may play a role in ILC2 recruitment in 
AERD.21,23,52
Asthma
Asthma is a heterogeneous disease although a majority of patients are thought to have type 2 
cytokines in their airways and are thus considered “type-2 high” asthmatics.53 The first 
report assessing levels of peripheral blood ILC2s in human asthma found no difference 
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between mild and severe asthmatics, as well as healthy controls.54 However, reports since 
have demonstrated increased activation status and numbers of ILC2s in samples from 
pediatric and adult asthmatics compared with controls.3,18,55–57 One report found increased 
peripheral blood ILC2s and Th2 cytokine levels in allergic asthmatics compared with 
healthy controls and patients with allergic rhinitis.18 The first study to assess airway ILC2s 
showed that cytokine producing ILC2s are increased in the sputum of severe asthmatics 
compared with mild asthmatics and healthy controls.3 Interestingly, several patients with 
elevated airway ILC2s had been administered systemic corticosteroids suggesting ILC2 
resistance to corticosteroids in these patients. A very recent report showed that TSLP 
imparts ILC2 corticosteroid resistance through STAT5 signaling and increased airway TSLP 
could be responsible for the presence of elevated ILC2s in severe asthma patients.58 
Treatments targeting upstream mediators such as TSLP59 that activate ILC2s remain fruitful 
areas of therapeutic development for patients with asthma not responsive to current therapy 
including corticosteroids.
Similar to findings of allergen challenge studies in allergic rhinitis, one report demonstrated 
that airway ILC2s are increased after allergen challenge in atopic asthmatics.60 The authors 
found that cytokine-producing ILC2s were increased in sputum and decreased in blood 24 h 
after allergen challenge. Another report, and in parallel with nasal polyp ILC2 studies, found 
that numbers of ILC2s in asthmatics correlated with numbers of eosinophils.57 Interestingly, 
a recent human and mouse ILC2 transcriptomic and epigenomic study showed that ILC2 
programs are specifically linked with known asthma susceptibility genes (including rora, 
smad3, gata3, il13, il18r1, and il1rl1) suggesting ILC2s may be key effectors in part 
regulated by genetic susceptibility in asthma.61 Overall, most studies suggest an increase of 
activated ILC2s in samples from asthma subjects and detailed animal studies (reviewed 
elsewhere12) support a role for ILC2s in airway hyperresponsiveness, lung eosinophilia, and 
mucus production.
An important finding in asthma is airway remodeling that likely contributes to declines in 
lung function over time. The cardinal features of remodeling include mucus metaplasia and 
secretion, airway smooth muscle hypertrophy and hyperplasia, as well as subepithelial 
fibrosis. ILC2s can contribute to airway remodeling through multiple mechanisms (Fig. 1) 
including through IL-13 production and recruitment of TGF-β-producing eosinophils via 
IL-5 secretion.2,62 In the normal airway, there is repair of tissue integrity after viral 
infections and other insults. Work in mice has shown that ILC2s promote airway repair after 
influenza infection through production of the growth factor amphiregulin.63 Thus, ILC2s 
may simultaneously promote aspects of pathologic tissue remodeling present in asthma as 
well as normal tissue repair.
Regulation of ILC2 function
The very recent discovery of a multitude of mediators that regulate ILC2 function suggests 
that ILC2s are finely tuned for activation and inhibition during inflammatory responses.14 
Here, we review major categories of ILC2-modulating mediators including epithelial 
cytokines, lipid mediators, neuro-immune molecules, and cellecell contact proteins.
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Airway epithelial cytokines
ILC2s were discovered in mice after characterization of lymphoid cells that produced high 
levels of IL-5 and IL-13 in response to IL-25 and IL-33.12 IL-25 (IL-17E) is an IL-17 family 
member and is secreted by epithelial cells, Th2 cells, and eosinophils, and binds to the 
IL-25R which is a heterodimer of IL-17RA and IL-17RB.64 IL-33 is present as a 
biologically active pro-form bound to chromatin in epithelial cells, endothelial cells, and 
macrophages and binds to a heterodimer of ST2 and the IL-1 receptor accessory protein.29,65 
Notably, though IL-25 and IL-33 potently activate ILC2s, these cytokines act on other 
immune cells including T cells, NKT cells, DCs, eosinophils, macrophages, basophils, and 
mast cells.66,67 Therefore, in vivo responses to IL-25 and IL-33 cannot be solely attributed 
to ILC2s.
ILC2s are a relatively rare population of cells which, along with being lineage-negative, 
likely led to their elusiveness to scientific community for decades. Despite being rare, ILC2s 
in vitro produce large amounts of IL-5 and IL-13 per cell (mg range for 50,000 cells) after 
stimulation with IL-33.68 As ILC2s are not antigen specific, the potential exists for all or 
most ILC2s in a tissue to be activated by available IL-33 or other mediator. This is in 
contrast to T cells that largely require antigen peptide presentation for full activation. 
Though ILC2s demonstrated impressive capacity for IL-5 and IL-13 production, IL-4 was 
not secreted by ILC2s stimulated with IL-33.68 Since the initial claims that ILC2s do not 
produce IL-4, an ample amount of data has now shown that ILC2s do make significant 
amounts of IL-4 when stimulated with other mediators such as cysteinyl leukotrienes 
(CysLTs).22,69 Importantly, IL-4 production by ILC2s may be a critical link to promoting 
adaptive Th2 cell responses.
After the initial mouse ILC2 studies with activation by IL-25 and IL-33, another group 
demonstrated that human ILC2s were activated by TSLP which potentiated ILC2 responses 
to IL-33.34 Prior to the discovery of ILC2s, TSLP was found elevated in samples from 
asthma and atopic dermatitis patients.31 Further, TSLP was known to control adaptive CD4+ 
Th2 cell responses through OX40/OX40L interactions with dendritic cells, but effects on 
innate cells were unclear.70 Therefore, the link between TSLP and ILC2 activation provided 
critical insight into mechanisms of type 2 inflammation.
Lipid mediators
Eicosanoids including CysLTs and PGD2 are generated during type 2 inflammation and 
have putative roles in promoting bronchoconstriction and inflammatory cell recruitment and 
activation.71 PGD2 was the first lipid shown to promote human ILC2 IL-13 production when 
combined with IL-2, IL-25 and IL-33.54 The same report additionally showed that Lipoxin 
A4 (LXA4) abrogated the PGD2-driven increase in IL-13. Our laboratory then showed that 
ILC2s from mouse lung and bone marrow highly express CysLT1 (high affinity receptor for 
leukotriene D4).22 ILC2s stimulated with leukotriene D4 (LTD4) rapidly produced high 
levels of IL-4, IL-5 and IL-13 in vitro and in vivo. Further work has shown that PGD2 and 
CysLTs promote human ILC2 cytokine production and chemotaxis.21,23,52 In addition to the 
inhibitory effects of LXA4 on ILC2 function, prostaglandin I2 (PGI2) and prostaglandin E2 
(PGE2) reduce the activation of both mouse and human ILC2s.72–74 Thus, depending on the 
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mileu of activating and inhibitory cytokines and lipid mediators present, there is likely a 
fine-tuning of ILC2 responses resulting in a dynamic regulation of these cells. Overall, lipid 
mediators that are important in allergic airway diseases are clearly important modulators of 
ILC2 function, even independent of epithelial cytokines.75
Interestingly, recent reports have shown that male and female steroid sex hormones regulate 
ILC2 function.76–79 Male mice were initially shown to have reduced HDM-induced lung 
inflammation compared with female mice and this difference was abolished with 
orchiectomy.77 Bone marrow from male mice lacking the androgen receptor transplanted 
into irradiated female wild type mice had similarly elevated lung ILC2 numbers and airway 
inflammation compared with female mice. Another report showed that circulating ILC2s are 
increased in women with severe asthma compared with men with severe asthma and 
testosterone suppressed ILC2-induced lung inflammation.79 In support of these reports, 
uterine ILC2s were demonstrated to be increased by estrogen treatment in WT mice and 
were nearly absent in mice deficient in estrogen receptors.78 Taken together, an array of lipid 
molecules including eicosanoids as well as sex steroids appear to be critical in the regulation 
of ILCs and ILC2 driven responses.
Neuro-immune control of ILC2s
The neuropeptide receptor NMUR1 is present on mouse and human ILC2s and stimulation 
with the neuropeptide neuromedin U (NMU) promotes Th2 cytokine production and type 2 
inflammatory tissue responses.80–82 Notably, the NMU/NMUR1/ILC2 axis represents a 
critical link between peripheral neurons and ILC2s that could contribute to 
neuroinflammation. More recent work has shown that ILC2s also express b-2 adrenergic 
receptors that respond to catecholamines secreted by sympathetic nerves and the adrenal 
medulla.83 Binding of the b-2 adrenergic receptor on ILC2s led to reduced activity and 
proliferation suggesting that b-2 is a negative regulator of ILC2s.
Very recently, mice deficient in pulmonary neuroendocrine cells (PNECs) demonstrated 
impairment in developing allergic lung inflammation.84 Interestingly, PNECs that produce 
several neuro-endocrine products were shown to localize with ILC2s at airway branch points 
and stimulate ILC2 cytokine production through calcitonin gene-related peptide (CGRP). 
Further, mucus cell hyperplasia was mediated through PNEC production of the neuro-
transmitter g-aminobutyric acid (GABA). Overall, tissue resident ILC2s appear to be highly 
regulated by neuro-immune and neuro-endocrine mechanisms.
Additional modulators of ILC2 function
Additional regulators of ILC2 function include TLA1/DR3 and ICOS/ICOSL.85–88 ICOS 
and ICOS ligand as well as DR3 and TL1A are classically considered “co-stimulatory” 
molecules that provide signals between antigen presenting cells (APCs) and T cells. 
However, these molecules are also expressed on a wide array of cell types and regulate both 
innate adaptive responses. DR3 and ICOS are present on mouse and human ILC2s and 
promote activation.85–88 Interestingly, ICOS-ICOSL also regulates Treg/ILC2 interactions 
that can also promote suppression of ILC2s.89,90 Suppressive cytokines including IL-10 and 
TGF-β were further found to reduce ILC2 function, a property similar to suppression of 
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other immune cells by these cytokines.91 Type 1 interferons produced during viral infections 
as well as IFNγ and IL-27 also reduce ILC2 responses.90 In an allergic response, the 
balance between such molecules that promote (DR3, ICOS) or dampen (IL-10, TGF-β, 
Tregs) ILC2 activation in type 2 inflammation may determine the subsequent severity of 
disease. Further, the availability of ligands or suppressive mediators in tissues may account 
for skewing towards or away from pathogenic allergic inflammation. Ongoing intensive 
investigations continue to uncover novel regulatory mechanisms of ILC2s at a rapid pace.
ILC2 regulation of adaptive Th2 responses
Initial allergen challenge mouse model studies of ILC2s largely utilized RAG-deficient mice 
(lack B and T cells but have ILC2s) in order to isolate the role of ILC2s separate from 
adaptive Th2 response.92,93 The downside of such models is that the contribution of ILC2s 
to lung inflammation in the presence of adaptive immunity could not be assessed. Recently, 
studies have utilized retinoid-related orphan receptor alpha (RORa) bone marrow transplant 
(BMT) models to attempt to overcome this obstacle.94,95 RORa is critical for ILC2 
development, but has limited if any role in CD4+ Th2 cell development or responses.94,96,97 
As RORa complete knockout mice have early neurologic demise, investigators have 
transferred RORa-deficient bone marrow into irradiated wild type hosts. This procedure also 
isolates the role of RORa to CD45 + hematopoietic cells. Notably, HDM and papain 
challenged RORa BMT mice that lack ILC2s did not generate an adaptive Th2 cell response, 
though these same mice undergoing a conventional OVA/alum models did have intact Th2 
responses.94 Potential mechanisms of ILC2-initiated Th2 cell activation include DC 
licensing and lymph node trafficking initiated by ILC2 IL-13 production as well as ILC2 
production of IL-4 induced by leukotriene D4.69,98 Despite the very low numbers of ILC2s 
in tissues, cellecell contact between ILC2s and other cell types including CD4+ T cells 
through MHCII and/or OX40 ligand has also been implicated in generating Th2 cell 
responses.99,100 Overall, ILC2s appear to have multiple roles in type 2 inflammation 
including early Th2 cytokine production as well as providing a critical link to adaptive Th2 
immunity.
ILC2 trafficking to the airway
During an inflammatory response, the degree of local proliferation of ILC2s versus ILC2 
migration from blood is largely unclear. This is an important question as potential 
therapeutic targets aimed at trafficking versus local activation and proliferation may be 
beneficial in type 2 inflammatory diseases. As ILC2s are CD45 + bone marrow derived 
cells, they presumably traffic to tissues through the blood though their longevity in tissues 
has not been explored. Recently, a few groups have reported how ILC2 migrate to the lung 
and other sites. Our laboratory tested the role of b1 and b2 integrin blockade during allergen 
challenge in mice.101 Human and mouse lung ILC2s expressed receptors for b1 and b2 
integrins which are used by cells to traffic into tissues. Blockade of b2 integrins, but not b1 
integrins, reduced ILC2 numbers in mouse lung after allergen challenge. Importantly, 
proliferation and apoptosis were not affected suggesting that targeting trafficking was 
mainly responsible for the reduced ILC2 numbers.
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Though IL-33 is known to regulate ILC2 activation and proliferation locally, a very recent 
report showed an additional role for IL-33 in bone marrow egress of ILC2s.102 IL-33 and 
ST2 deficient mice had increased ILC2 progenitors in the bone marrow and fewer in the 
mediastinal lymph nodes (MLN) and lungs at steady state. Administration of IL-33 reversed 
these changes and one mechanism highlighted was IL-33-induced reduction of CXCR4 to 
promote egress from the bone marrow. Similar to our studies, the authors also found that 
Alternaria exposure to the airways of mice leads ILC2 egress from bone marrow.101 IL-25 
also appears to have a role in ILC2 trafficking as both IL-25 and helminth infection led to 
trafficking of ILC2s from the gut lamina propria to a diverse number of sites including the 
lung.103 This migration of ILC2s occurred in lymphatics and was dependent on sphingosine 
1-phosphate (S1P) for chemotaxis. Thus, though epithelial cytokines IL-25 and IL-33 are 
largely thought to regulate tissue resident ILC2 responses locally, these reports show a role 
for both cytokines in ILC2 trafficking responses that will require critical evaluation in 
humans as therapeutics targeting these cytokines are developed.
ILC2 plasticity in airway disease
Though ILC2s were initially considered fully differentiated cells that produce a distinct 
repertoire of cytokines, several reports quickly changed this paradigm and clearly showed 
that ILC2s, along with other ILCs, demonstrate plasticity depending on the cytokine milieu 
(Fig. 2). Initial studies showed that pro-inflammatory IL-1 cytokines IL-1a and IL-1b 
potently induce human ILC2 proliferation and Th2 cytokine production.41,104 However, in 
the presence of IL-12, IL-1b reduced ILC2 GATA3 expression and transformed ILC2s into 
an ILC1 phenotype (or “ex-ILC2”) that produce IFNγ. The IL-1 family cytokine IL-18 also 
appears to support ILC2 to ILC1 transformation.105 Further studies have additionally 
demonstrated that notch signaling, sustained IL-33 presence and CysLTs induce IL-17 
production from ILC2s.106,107 As subsets of severe asthma patients have airway neutrophilia 
and elevated levels of IL-17 or IFNγ,108 such ILC2 plasticity to become IFNγ or IL-17 
producers may contribute to neutrophilia and associated cytokine responses.
Whether such plasticity contributes to human airway diseases in vivo remains unknown. In 
previous work, a mouse model of obesity-induced asthma showed that IL-1b produced after 
high fat diet intake led to ILC3 generation and AHR, thus supporting a role for ILC3 in an 
asthma model.109 ILC3s produce IL-17 (a neutrophil chemotactic cytokine) that could 
contribute to neutrophilic inflammation found in some endotypes of asthma, especially non-
allergic and severe asthma.110 IL-17 has been detected in elevated levels in some patients 
with severe asthma though whether the source is ILC3s is not known.111
Finally, a distinct subset of ILC2s were recently demonstrated to produce IL-10 during 
papain or IL-33 challenge and represented a large portion of the IL-10 producing cells in the 
lung.112 In vitro, the addition of IL-2 along with retinoic acid could induce IL-10 production 
from ILC2s.112 In vivo, IL-2 enhanced expansion of IL-10 producing ILC2s and reduced 
lung eosinophila in RAG deficient mice (have ILC2s but lack T or B cells) treated with 
IL-33.112 Overall, the ILC community is at an early stage in the understanding of how ILC 
plasticity is regulated, especially in humans under conditions of disease.
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Summary
The discovery of group 2 innate lymphoid cells has completely altered classical paradigms 
of allergic airway disease. Despite a rapid increase in the number of ILC2 publications, we 
are still in our infancy when it comes to an understanding of their roles in human allergic 
airway diseases. Multiple studies have shown an association of asthma, CRS, AERD, and 
allergic rhinitis with increased ILC2 levels and activation of tissue ILC2s which supports 
their possible role in these diseases. Mouse models demonstrate important contributions by 
ILC2s in promotion of tissue eosinophilia, AHR, and mucus production in the airway. 
Recent discoveries demonstrating how ILC2s promote adaptive Th2 responses, are regulated 
by neuronal mediators, and that ILC2s undergo plasticity changes to produce ILC1 or ILC3 
cytokines have expanded our understanding of these impressive cells. Importantly, targeting 
upstream or downstream ILC2 mediators may lead to promising potential therapeutic 
strategies for allergic airway diseases.
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Fig. 1. 
ILC2 contributions to airway remodeling in asthma and normal tissue repair responses. 
Activated ILC2s produce IL-13 that promotes subepithelial fibrosis, airway hyper-
responsiveness (AHR), smooth muscle increases, and epithelial mucus production (along 
with IL-9). Further, ILC2s produce IL-5 which induces proliferation of eosinophils that 
express the pro-fibrotic growth factor TGF-β. In the normal airway, amphiregulin production 
by ILC2s may maintain normal tissue homeostasis and repair lung structures after viral 
infections.
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Fig. 2. 
Activated ILC2 responses and plasticity in allergic airway diseases. TSLP, IL-33, and IL-25 
are induced by epithelial damage after exposure to allergens, specific viruses or irritants. 
These cytokines, as well as cysteinyl leukotrienes (CysLTs) and prostaglandin D2 (PGD2) 
induce Th2 cytokine production from ILC2s. IL-5 promotes tissue eosinophilia, IL-13 
induces AHR, mucus production and immune cell recruitment, and IL-9 promotes mast cell 
accumulation and mucus production (not shown). CysLTs specifically induce ILC2 IL-4 
production that can promote Th2 cell differentiation and IgE class switching from B cells. 
ILC2s can also be converted to ILC1-like cells by IL-1b, IL-12 and IL-18 leading to 
production of IFNγ and TNFα. Sustained production of IL-33, notch ligands, and CysLTs 
also induce IL-17 from ILC2s. IL-1b may also directly promote ILC3 generation in obesity. 
Th1/Th17 cytokines may promote neutrophilic airway disease as well as AHR in some 
circumstances. Inhibitory pathways not shown, and reviewed elsewhere.91
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